Imagion Biosystems Limited
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a IBXXF research report →
Companyimagionbiosystems.com
Imagion Biosystems Limited provides medical imaging technologies based on superparamagnetic relaxometry for cancer and disease detection, and monitoring therapy. It has activities in nanotechnology; biotechnology; cancer diagnostics; and superparamagnetic relaxometry. The company develops MagSense, which is in Phase I clinical trials for the treatment of HER2 breast cancers; and PrecisionMRX, an iron oxide nanoparticle to detect cancer.
- CEO
- Robert Romeo Proulx
- IPO
- 2020
- Employees
- 11
- HQ
- San Diego, CA, US
Price Chart
Valuation
- Market Cap
- $2.21M
- P/E
- -1.10
- P/S
- 111.59
- P/B
- -2.19
- EV/EBITDA
- -1.01
- Div Yield
- 0.00%
Profitability
- Gross Margin
- -2293.56%
- Op Margin
- -16189.90%
- Net Margin
- -16746.15%
- ROE
- 142.99%
- ROIC
- -1025.50%
Growth & Income
- Revenue
- $0 · -100.00%
- Net Income
- $-4,307,762 · -108.41%
- EPS
- $-0.02 · 66.52%
- Op Income
- $-3,583,483
- FCF YoY
- -218.12%
Performance & Tape
- 52W High
- $0.04
- 52W Low
- $0.01
- 50D MA
- $0.01
- 200D MA
- $0.01
- Beta
- -0.19
- Avg Volume
- 961
Get TickerSpark's AI analysis on IBXXF
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Our IBXXF Coverage
We haven't published any research on IBXXF yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate IBXXF Report →